

# Cristina P Rodriguez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8889132/publications.pdf>

Version: 2024-02-01

27  
papers

359  
citations

1163117

8  
h-index

794594

19  
g-index

27  
all docs

27  
docs citations

27  
times ranked

704  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 837-845.	7.0	120
2	A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2740-2748.	7.0	76
3	Human Papillomavirus: Changing Paradigms in Oropharyngeal Cancer. <i>Current Oncology Reports</i> , 2010, 12, 115-120.	4.0	27
4	FOXO1 drives HPV+ HNSCC sensitivity to WEE1 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28287-28296.	7.1	24
5	Current and Emerging Standards of Concomitant Chemoradiotherapy. <i>Seminars in Oncology</i> , 2008, 35, 211-220.	2.2	19
6	Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: Impact of changing disease epidemiology on contemporary trial design. <i>Head and Neck</i> , 2015, 37, 1583-1589.	2.0	17
7	Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies. <i>Head and Neck</i> , 2018, 40, 584-589.	2.0	13
8	Performance status (<scp>PS</scp>) as a predictor of poor response to immune checkpoint inhibitors (<scp>ICI</scp>) in recurrent/metastatic head and neck cancer (<scp>RMHNSCC</scp>) patients. <i>Cancer Medicine</i> , 2022, 11, 4104-4111.	2.8	11
9	Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2017, 127, 1583-1588.	2.0	8
10	Racial disparity in oncologic and quality of life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial. <i>Cancer</i> , 2018, 124, 2841-2849.	4.1	7
11	Phase I/II trial of pembrolizumab(P) and vorinostat(V) in recurrent metastatic head and neck squamous cell carcinomas (HN) and salivary gland cancer (SGC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 6025-6025.	1.6	7
12	Salivary Gland Malignancies. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1145-1157.	2.2	6
13	The role of elective neck dissection in high-grade parotid malignancy: A hospital-based cohort study. <i>Laryngoscope</i> , 2020, 130, 1487-1495.	2.0	6
14	Postoperative Combined Modality Treatment in High Risk Resected Locally Advanced Squamous Cell Carcinomas of the Head and Neck (HNSCC). <i>Frontiers in Oncology</i> , 2018, 8, 588.	2.8	4
15	Wound Complications in Head and Neck Squamous Cell Carcinomas After Anti-PD-1 Therapy. <i>Laryngoscope</i> , 2019, 129, E428-E433.	2.0	4
16	The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 196-205.	1.4	4
17	Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure. <i>Oncologist</i> , 2018, 23, 147-149.	3.7	2
18	A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly cisplatin and docetaxel in borderline resectable head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6034-6034.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Patterns of recurrence in patients with sinonasal undifferentiated carcinoma (SNUC) treated with multimodality therapy at a single center.. Journal of Clinical Oncology, 2017, 35, e17575-e17575.	1.6	1
20	End-of-life health care utilization (EOLHCU) in patients with recurrent, metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with immune checkpoint inhibitors (IO).. Journal of Clinical Oncology, 2020, 38, e18516-e18516.	1.6	1
21	Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes. Journal of Gastrointestinal Cancer, 2017, 48, 181-189.	1.3	0
22	Impact of ECOG performance status on recurrent/metastatic head and neck squamous cell carcinomas treated with anti-PD1 inhibitors.. Journal of Clinical Oncology, 2021, 39, e18004-e18004.	1.6	0
23	Timing of postoperative radiation therapy and survival in resected salivary gland cancers: Long-term results from a single institution.. Journal of Clinical Oncology, 2021, 39, e18052-e18052.	1.6	0
24	Clonal repopulation dynamics in recurrent human papillomavirus-associated head and neck cancer.. Journal of Clinical Oncology, 2017, 35, e17517-e17517.	1.6	0
25	Prognostic significance of performance status in patients with head and neck squamous cell carcinomas (HNSCC) receiving immune checkpoint monoclonal antibodies (ICmAB) in a single institution.. Journal of Clinical Oncology, 2017, 35, e17506-e17506.	1.6	0
26	End-of-life health care utilization (EOLHCU) in patients with thoracic, head and neck cancers with or without phase I study participation at a single institution.. Journal of Clinical Oncology, 2020, 38, e19153-e19153.	1.6	0
27	High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors. Journal of Palliative Medicine, 2021, , .	1.1	0